(VIANEWS) – The Market ended the session with CELYAD ONCOLOGY (CYAD.BR) jumping 10.33% to €0.26 on Monday, following the last session’s upward trend. BEL 20 rose 0.46% to €4,131.65, after three consecutive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.
About CELYAD ONCOLOGY
Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, CELYAD ONCOLOGY has a trailing twelve months EPS of €-1.36.
Volume
Today’s last reported volume for CELYAD ONCOLOGY is 17381 which is 23.83% above its average volume of 14036.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CELYAD ONCOLOGY’s stock is considered to be overbought (>=80).
Volatility
CELYAD ONCOLOGY’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.42%, a negative 0.38%, and a positive 2.94%.
CELYAD ONCOLOGY’s highest amplitude of average volatility was 2.70% (last week), 3.34% (last month), and 2.94% (last quarter).
More news about CELYAD ONCOLOGY (CYAD.BR).
